Skip to Main Content

Among the drug industry’s least-escapable buzzphrases is “value-based contracting,” a system under which payers shell out for pricey drugs only when they work, creating a theoretical win-win that increases access and cuts costs all the while.

So why hasn’t the idea caught on?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED